CamerlingoS, et al. Clinical impact of gender and age at onset on disease trajectory in primary progressive multiple sclerosis patients. Mult Scler J2024.
2.
AchironADreyer-AlsterSGurevichM, et al. Definitions of primary-progressive multiple sclerosis trajectories by rate of clinical disability progression. Mult Scler Relat Disord2021; 50: 102814.
3.
MarrodanMBensiCPappollaA, et al. Disease activity impacts disability progression in primary progressive multiple sclerosis. Mult Scler Relat Disord2020; 39: 101892.
4.
VuralADerleESayat-GürelG, et al. Predictors of progression in primary progressive multiple sclerosis in a large Turkish cohort. Mult Scler Relat Disord2020; 38: 101520.
5.
FernándezOFernándezVArbizuT, et al. Characteristics of multiple sclerosis at onset and delay of diagnosis and treatment in Spain (the Novo study). J Neurol2010; 257(9): 1500–1507.
6.
KaufmannMKuhleJPuhanMA, et al. Factors associated with time from first-symptoms to diagnosis and treatment initiation of multiple sclerosis in Switzerland. Mult Scler J Exp Transl Clin2018; 4(4): 2055217318814562.
7.
CohenJATrojanoMMowryEM, et al. Leveraging real-world data to investigate multiple sclerosis disease behavior, prognosis, and treatment. Mult Scler2020; 26(1): 23–37.
8.
BoveRBevanCCrabtreeE, et al. Toward a low-cost, in-home, telemedicine-enabled assessment of disability in multiple sclerosis. Mult Scler2019; 25(11): 1526–1534.
9.
OnuorahHMCharronOMeltzerE, et al. Enrollment of non-white participants and reporting of race and ethnicity in phase III trials of multiple sclerosis DMTs: A systematic review. Neurology2022; 98: E880–E892.
